The role of stereotactic body radiotherapy in switching systemic therapy for patients with extracranial oligometastatic renal cell carcinoma.

Cem OnalPervin HurmuzOzan Cem GulerGuler YavasBurak TilkiEzgi OymakCagdas YavasGokhan Ozyigit

Published in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2022)

The SBRT to oligometastatic sites is an effective and safe treatment option for ≤ 5 metastases in RCC patients by providing favorable survival and delaying NEST change.

Keyphrases

renal cell carcinoma
end stage renal disease
radiation therapy
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
prognostic factors
patient reported outcomes
free survival